The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

New ISO standards categorize SVIOLs into multifocal, EDOF, and FVR IOLs, requiring rigorous clinical testing for ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and ...

Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.